191 related articles for article (PubMed ID: 21327054)
21. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys.
Boado RJ; Ka-Wai Hui E; Zhiqiang Lu J; Pardridge WM
Biotechnol Bioeng; 2014 Nov; 111(11):2317-25. PubMed ID: 24889100
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.
Zhou QH; Sumbria R; Hui EK; Lu JZ; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 2011 Nov; 339(2):618-23. PubMed ID: 21831964
[TBL] [Abstract][Full Text] [Related]
23. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Aug; 97(6):1376-86. PubMed ID: 17286273
[TBL] [Abstract][Full Text] [Related]
24. Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein.
Lu JZ; Boado RJ; Hui EK; Zhou QH; Pardridge WM
Biotechnol Bioeng; 2011 Aug; 108(8):1954-64. PubMed ID: 21351076
[TBL] [Abstract][Full Text] [Related]
25. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor.
Coloma MJ; Lee HJ; Kurihara A; Landaw EM; Boado RJ; Morrison SL; Pardridge WM
Pharm Res; 2000 Mar; 17(3):266-74. PubMed ID: 10801214
[TBL] [Abstract][Full Text] [Related]
26. Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy.
Ou W; Yang J; Simanauskaite J; Choi M; Castellanos DM; Chang R; Sun J; Jagadeesan N; Parfitt KD; Cribbs DH; Sumbria RK
J Neuroinflammation; 2021 Dec; 18(1):312. PubMed ID: 34972522
[TBL] [Abstract][Full Text] [Related]
27. Selective plasma pharmacokinetics and brain uptake in the mouse of enzyme fusion proteins derived from species-specific receptor-targeted antibodies.
Zhou QH; Boado RJ; Pardridge WM
J Drug Target; 2012 Sep; 20(8):715-9. PubMed ID: 22845843
[TBL] [Abstract][Full Text] [Related]
28. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
Biotechnol Bioeng; 2008 Feb; 99(2):475-84. PubMed ID: 17680664
[TBL] [Abstract][Full Text] [Related]
29. Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody.
Pardridge WM
Expert Opin Drug Deliv; 2015 Feb; 12(2):207-22. PubMed ID: 25138991
[TBL] [Abstract][Full Text] [Related]
30. Genetic engineering of a bifunctional IgG fusion protein with iduronate-2-sulfatase.
Lu JZ; Hui EK; Boado RJ; Pardridge WM
Bioconjug Chem; 2010 Jan; 21(1):151-6. PubMed ID: 20000684
[TBL] [Abstract][Full Text] [Related]
31. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.
Boado RJ; Zhang Y; Wang Y; Pardridge WM
Biotechnol Bioeng; 2009 Mar; 102(4):1251-8. PubMed ID: 18942151
[TBL] [Abstract][Full Text] [Related]
32. Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
Drug Metab Dispos; 2012 Oct; 40(10):2021-5. PubMed ID: 22822036
[TBL] [Abstract][Full Text] [Related]
33. Genetic engineering of IgG-glucuronidase fusion proteins.
Boado RJ; Pardridge WM
J Drug Target; 2010 Apr; 18(3):205-11. PubMed ID: 19827970
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein.
Fu A; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Brain Res; 2010 Nov; 1360():193-7. PubMed ID: 20833153
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice.
Sumbria RK; Zhou QH; Hui EK; Lu JZ; Boado RJ; Pardridge WM
Mol Pharm; 2013 Apr; 10(4):1425-31. PubMed ID: 23410508
[TBL] [Abstract][Full Text] [Related]
36. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses.
Pardridge WM
Bioconjug Chem; 2008 Jul; 19(7):1327-38. PubMed ID: 18547095
[TBL] [Abstract][Full Text] [Related]
37. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey.
Boado RJ; Pardridge WM
Drug Metab Dispos; 2009 Dec; 37(12):2299-304. PubMed ID: 19741036
[TBL] [Abstract][Full Text] [Related]
38. Imaging amyloid plaque in Alzheimer's disease brain with a biotinylated Aβ peptide radiopharmaceutical conjugated to an IgG-avidin fusion protein.
Sumbria RK; Boado RJ; Pardridge WM
Bioconjug Chem; 2012 Jun; 23(6):1318-21. PubMed ID: 22624578
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor.
Boado RJ; Zhou QH; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Feb; 7(1):237-44. PubMed ID: 19921848
[TBL] [Abstract][Full Text] [Related]
40. GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Wang Y; Pardridge WM
Biotechnol Bioeng; 2008 Jun; 100(2):387-96. PubMed ID: 18080333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
